Truly transformative healthcare companies often solve "boring" but fundamental problems. Instead of tackling surface-level symptoms (e.g., appointment booking), the best founders dig deep to fix the complex, underlying infrastructure issues of the healthcare system, creating a durable competitive moat.

The biggest challenge in healthcare AI is acquiring labeled data. Guardant's business model is structured to not only generate a massive proprietary dataset of patient samples and outcomes but to get paid by insurers and pharma to do so, creating a self-funding data flywheel.

Pitches for an "Uber of healthcare" fundamentally misunderstand the industry. Healthcare isn't a simple, one-off transaction like a taxi ride; it's a complex, ongoing human relationship that requires continuous connection, which purely transactional models fail to provide.

There is a profound mismatch between the critical role of diagnostics in guiding medical treatment and their reimbursement value. This value gap highlights a systemic inefficiency and a major opportunity for companies that can demonstrate improved patient outcomes and system-wide savings.

The future business model for health tech will shift from subscriptions (SaaS) to outcomes. Vendors will be paid based on the tangible results they generate, such as cost savings or improved patient health, aligning incentives.

In healthcare, the user, recommender, and payer are often different entities. A clinically effective product can easily fail if it's not inserted into the right point in the value chain where a stakeholder is both willing and incentivized to pay for it.

Disruptive MedTech ideas attract investment, but they are high-risk. Founders should de-risk these big bets by developing market access and commercial strategies simultaneously with product development, not after FDA approval.

Many companies fail by building a technology and then searching for a problem. VedaBio exemplifies the opposite approach: first defining the "perfect product" for a specific need (urgent care testing), and then applying the right technology to build it.

Regulatory approval is just an early milestone in diagnostics. True success requires solving for reimbursement, manufacturing scale, supply chain, and commercialization from the very beginning. These non-scientific hurdles are critical for building a viable business.